Sign In
to Vote &
Create Storyboards.
 
Merck Serono, the biopharmaceutical division of Merck, has announced that The Lancet Oncology has published results from the Phase III trial of its investigational MUC1 antigen specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non- small cell lung cancer (NSCLC), known as the START* trial.Data included in the publication1, and first presented at the American Society of Clinical Oncology (ASCO) 20132, showed that the primary...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard